RSVPreF3 OA vaccine clinical trials

An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

This study is looking at an RSV vaccine for people aged 60 and over. It aims to find the best time for repeat vaccination, understand long-term protection, and give the vaccine to people who previously received a dummy treatment.